phrykt

Sionna Therapeutics, Inc. (SION): who owns it and who trades it

As of Nov 16, 2026, SION insiders reported 62 open-market sales worth $95.4M and no purchases in the last 12 months, with 60% of the sale value made under pre-set 10b5-1 plans. The largest seller was Peter A. Thompson (Director), with $49.3M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Sionna Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SION

147 funds and institutions reported SION shares worth $2.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 21.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Ra Capital Management, L.P.21.9%
Tpg Gp A, LLC14.4%
Viking Global Investors LP7.1%
Atlas Venture Life Science Advisors, LLC6.6%
Orbimed Advisors LLC5.7%
Enavate Sciences Gp, LLC5.5%
Adage Capital Partners Gp, L.l.c.3.5%
JPMorgan Chase & Co3.3%
BlackRock, Inc.3.3%
Jennison Associates LLC2.6%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.9.91M21.94%$436MNo change
Tpg Gp A, LLC6.49M14.39%$286MNo change
Viking Global Investors LP3.20M7.08%$141MNo change
Atlas Venture Life Science Advisors, LLC3.00M6.63%$132MNo change
Orbimed Advisors LLC2.56M5.66%$112M-28%
Enavate Sciences Gp, LLC2.48M5.49%$109MNo change
Adage Capital Partners Gp, L.l.c.1.60M3.54%$70.4M+967%
JPMorgan Chase & Co1.49M3.30%$64.1M–
BlackRock, Inc.1.47M3.27%$64.9M+14%
Jennison Associates LLC1.17M2.60%$51.6M-19%
Citadel Advisors LLC1.15M2.54%$50.5M-2%
Vanguard Capital Management LLC1.13M2.51%$49.8M+10%
State Street Corp1.02M2.26%$44.9M+35%
Perceptive Advisors LLC905,0002.00%$39.8M+37%
Deerfield Management Company, L.P.680,9161.51%$30M-30%
California State Teachers Retirement System653,3391.45%$14.9M+75169%
Siren, L.L.C.610,5151.35%$26.9M+104%
T. Rowe Price Associates478,0161.06%$21M-37%
Eventide Asset Management, LLC474,9811.05%$20.9M-26%
Geode Capital Management, LLC457,1451.01%$20.1M+17%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SION insiders reported $0 of open-market purchases and $95.4M of sales. 60% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$95.4M
62 trades, 7 people
Sales under a 10b5-1 plan
60%
Share of sale value
Latest trade
Sep 17, 2026
Filed Sep 21, 2026

Purchases and sales by month

$25.4M$25.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 17, 2026Ra Capital Management, L.P. +5DirectorSale3.42M$6.32$21.6MForm 4
Sep 17, 2026Ra Capital Management, L.P. +5DirectorSale33,800$7.46$252KForm 4
Jul 7, 2026Peter A. ThompsonDirectorSale plan85,918$44.86$3.9MForm 4
Jul 6, 2026Jennifer FitzpatrickChief Legal OfficerSale plan10,250$43.60$447KForm 4
Jun 30, 2026Peter A. ThompsonDirectorSale plan115,844$45.50$5.3MForm 4
May 27, 2026Peter A. ThompsonDirectorSale plan101$44.49$4.5KForm 4
May 11, 2026Peter A. ThompsonDirectorSale plan184,639$46.22$8.5MForm 4
May 8, 2026Peter A. ThompsonDirectorSale plan59,767$44.58$2.7MForm 4
May 7, 2026Peter A. ThompsonDirectorSale plan48,546$44.61$2.2MForm 4
Apr 18, 2026Peter A. ThompsonDirectorSale plan2,948$44.52$131KForm 4
Apr 17, 2026Peter A. ThompsonDirectorSale plan52,397$44.68$2.3MForm 4
Apr 16, 2026Peter A. ThompsonDirectorSale plan226,906$45.34$10.3MForm 4
Apr 15, 2026Peter A. ThompsonDirectorSale plan235,863$44.64$10.5MForm 4
Apr 14, 2026Peter A. ThompsonDirectorSale plan47,814$44.51$2.1MForm 4
Mar 5, 2026Jennifer FitzpatrickChief Legal OfficerSale plan10,250$33.86$347KForm 4
Feb 3, 2026Peter A. ThompsonDirectorSale plan29,063$44.58$1.3MForm 4
Feb 2, 2026Peter A. ThompsonDirectorSale plan1,890$44.57$84.2KForm 4
Jan 22, 2026Jon Winkelried +210% ownerSale250,000$40.00$10MForm 4
Dec 24, 2025OrbiMed Capital GP VIII LLC +1DirectorSale plan33,356$44.55$1.5MForm 4
Dec 19, 2025OrbiMed Capital GP VIII LLC +1DirectorSale plan875$44.49$38.9KForm 4
Dec 18, 2025OrbiMed Capital GP VIII LLC +1DirectorSale plan100$44.49$4.4KForm 4
Dec 17, 2025OrbiMed Capital GP VIII LLC +1DirectorSale plan900$44.50$40KForm 4
Dec 5, 2025Jennifer FitzpatrickChief Legal OfficerSale plan10,250$40.52$415KForm 4
Nov 26, 2025Orbimed Advisors Llc +1DirectorSale plan1,600$44.49$71.2KForm 4
Nov 25, 2025Orbimed Advisors Llc +1DirectorSale plan11,890$44.60$530KForm 4
Nov 24, 2025Orbimed Advisors Llc +1DirectorSale plan94,583$44.54$4.2MForm 4
Nov 21, 2025Peter Kolchinsky +5DirectorSale7,609$39.50$301KForm 4
Nov 21, 2025Peter Kolchinsky +5DirectorSale1,210$39.50$47.8KForm 4
Nov 21, 2025Peter Kolchinsky +5DirectorSale9,924$39.50$392KForm 4
Nov 21, 2025Peter Kolchinsky +5DirectorSale6,440$39.50$254KForm 4
Nov 20, 2025Peter Kolchinsky +5DirectorSale150$39.89$6KForm 4
Nov 20, 2025Peter Kolchinsky +5DirectorSale1,235$39.89$49.3KForm 4
Nov 20, 2025Peter Kolchinsky +5DirectorSale801$39.89$32KForm 4
Nov 20, 2025Peter Kolchinsky +5DirectorSale947$39.89$37.8KForm 4
Nov 20, 2025Peter Kolchinsky +5DirectorSale96$40.50$3.9KForm 4
Nov 20, 2025Peter Kolchinsky +5DirectorSale512$40.50$20.7KForm 4
Nov 20, 2025Peter Kolchinsky +5DirectorSale604$40.50$24.5KForm 4
Nov 20, 2025Peter Kolchinsky +5DirectorSale788$40.50$31.9KForm 4
Nov 19, 2025Ra Capital Management, L.P. +5DirectorSale9$40.61$365Form 4
Nov 19, 2025Ra Capital Management, L.P. +5DirectorSale8$40.61$325Form 4
Nov 19, 2025Ra Capital Management, L.P. +5DirectorSale12$40.61$487Form 4
Nov 19, 2025Ra Capital Management, L.P. +5DirectorSale2$40.61$81Form 4
Nov 19, 2025Ra Capital Management, L.P. +5DirectorSale14,325$40.01$573KForm 4
Nov 19, 2025Ra Capital Management, L.P. +5DirectorSale12,126$40.01$485KForm 4
Nov 19, 2025Ra Capital Management, L.P. +5DirectorSale18,684$40.01$748KForm 4
Nov 19, 2025Ra Capital Management, L.P. +5DirectorSale2,276$40.01$91.1KForm 4
Nov 18, 2025Ra Capital Management, L.P. +5DirectorSale1,770$39.57$70KForm 4
Nov 18, 2025Ra Capital Management, L.P. +5DirectorSale2,728$39.57$108KForm 4
Nov 18, 2025Ra Capital Management, L.P. +5DirectorSale332$39.57$13.1KForm 4
Nov 18, 2025Ra Capital Management, L.P. +5DirectorSale2,092$39.57$82.8KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale53$42.10$2.2KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale433$42.10$18.2KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale280$42.10$11.8KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale331$42.10$13.9KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale10,707$41.05$440KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale9,063$41.05$372KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale13,964$41.05$573KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale1,701$41.05$69.8KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale13,734$40.20$552KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale11,626$40.20$467KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale17,913$40.20$720KForm 4
Nov 17, 2025Ra Capital Management, L.P. +5DirectorSale2,182$40.20$87.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Peter A. ThompsonDirector–$49.3MJul 7, 2026
Ra Capital Management, L.P.Director, 10% owner–$27.3MSep 17, 2026
Jon Winkelried10% owner–$10MJan 22, 2026
Orbimed Advisors LlcDirector–$4.8MNov 26, 2025
OrbiMed Capital GP VIII LLCDirector–$1.6MDec 24, 2025
Jennifer FitzpatrickChief Legal Officer–$1.2MJul 6, 2026
Peter KolchinskyDirector, 10% owner–$1.2MNov 21, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SION short interest

Moderate short interest. 9.3% of SION shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went down 11%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 4.21M SION shares were sold short, 9.3% of the shares outstanding, up 14.6% from the report before. At the average daily volume of 1.03M shares, buying them all back would take about 4.1 trading days (days to cover).

Shares short, % of all shares

9.31%May 15Oct 3012.8%

Days to cover

4.1May 15Oct 3016.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.21M9.31%+15%1.03M4.1
Oct 15, 20263.68M8.13%-3%983,0943.7
Sep 30, 20263.80M8.40%-4%1.65M2.3
Sep 15, 20263.97M8.77%-8%1.28M3.1
Aug 31, 20264.30M9.51%+1%1.64M2.6
Aug 14, 20264.25M9.40%+1%7.35M1.0
Jul 31, 20264.20M9.29%-20%618,0006.8
Jul 15, 20265.26M11.64%-5%456,75311.5
Jun 30, 20265.52M12.23%+11%544,38710.1
Jun 15, 20265.00M11.07%+8%360,22013.9
May 29, 20264.64M10.27%-2%319,20414.5
May 15, 20264.74M10.50%+12%421,44911.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Sionna Therapeutics company events

Sionna Therapeutics filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Sep 14, 2026LeadershipDeparture of Chief Business Officer; Officer Roles In connection with the Restructuring, the employment of Caroline Stark Beer, M.B.A., the Company’s Chief Business Officer, was terminated without cause, effective as of September 15, 2026. Filing
  3. Aug 10, 2026AnnouncementSionna Therapeutics, Inc., or the Company, announced topline data from both its PreciSION CF Phase 2a proof-of-concept trial of SION-719 when added to current standard of care and its Phase 1 trial of SION-451-based proprietary dual combinations in healthy subjects. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jun 18, 2026VoteReported shareholder vote results. Filing
  6. May 12, 2026ResultsReleased financial results. Filing
  7. Mar 2, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Sionna Therapeutics financials

Famous investors that hold SION

4 of the 50 well-known investors we track reported holding SION in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $16.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20263.20M$16.8M0.1%No change
Israel Englander · Millennium ManagementQ3 20261.46M$7.7M0.0%+429%
Steve Cohen · Point72 Asset ManagementQ3 2026263,401$1.4M0.0%+434%
Ken Griffin · Citadel AdvisorsQ3 202616,188$85.1K0.0%-99%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SION in the last 120 days.

FiledHolderFormStake
Nov 9, 2026THE GOLDMAN SACHS GROUP, INC.13G5.8%
Nov 9, 2026THE GOLDMAN SACHS GROUP, INC.13G5.8%

Questions about Sionna Therapeutics, Inc. (SION) stock

Who owns the most SION stock?

The largest reported owner of Sionna Therapeutics, Inc. (SION) is Ra Capital Management, L.P., with 21.9% of the company. In total, 147 funds and institutions reported holding SION at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are SION insiders buying or selling?

In the last 12 months, SION insiders reported no open-market purchases and 62 sales worth $95.4M. The latest trade was on Sep 17, 2026. See every trade.

What is the short interest in SION?

As of Oct 30, 2026, 4.21M SION shares were sold short, 9.3% of the shares outstanding, up 14.6% from the report before. At the average daily volume of 1.03M shares, buying them all back would take about 4.1 trading days (days to cover). See the history.

Which famous investors hold SION?

4 of the 50 well-known investors we track reported SION in their latest 13F filing, including Andreas Halvorsen, Israel Englander, Steve Cohen. The largest position is worth $16.8M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.